Q-omics provides the consensus-scored UFL1 profile across patient tissues and cancer cell-line models. UFL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UFL1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, UFL1 RNA expression shows 20,282 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where UFL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UFL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UFL1 survival associations across molecular data types. UFL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UFL1 RNA expression–survival associations across cancer types. High UFL1 expression shows unfavorable associations in CESC, but favorable associations in KIRC, READ, PRAD, SKCM and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UFL1 RNA expression.
This table summarizes UFL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UFL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UFL1 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in KIRC, LUAD and CHOL. The THCA box plot shows higher UFL1 RNA expression in normal versus tumor tissue (log2 FC = −0.708, t-test p < 0.001).
This table shows molecular features associated with UFL1 in patient tissues and cancer cell lines. In patient samples, UFL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UFL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
